Cambridge Nutritional Sciences (LSE:CNSL), the specialist medical diagnostics business, is in focus after setting 10 November 2026 as the date for its half-year results for the six months to 30 September 2026, alongside an online investor presentation. That update follows a difficult full year in which Revenue fell and losses widened, and investors are looking for evidence that a restructuring completed in March 2026 is feeding through.
What the company does
Cambridge Nutritional Sciences develops and manufactures diagnostic tests, with a focus on food sensitivity. Its main revenue streams are FoodPrint, a laboratory-based testing system, Food Detective, a rapid test product, and CNSLab, its own testing services business. It sells through distributors in a range of international markets as well as through partners in the UK.
Latest developments
The most detailed recent picture comes from full-year results for the year to 31 March 2026, published in September 2026. Revenue fell 16.3% to £7.0 million from £8.3 million, which the company attributed to weaker international demand, including the loss of distributor clients in the Americas and Europe. Food Detective sales fell 46% and FoodPrint fell 12%, while India grew 23% in sterling terms and CNSLab testing rose 11%.
The company completed a UK restructuring in March 2026, reducing full-time headcount from 76 to 58, and the board voluntarily accepted a 10% salary cut. It also reorganised sales, creating a new customer success team and appointing Erik Melgaard Pedersen as global sales director in June 2026. A new five-year agreement was signed with its UK white-label partner, although its value was not disclosed. Operationally, production yields improved to 64.7% from 52.3%.
Financial picture
Gross Margin improved to 67.8% from 65.3%, but adjusted EBITDA swung to a loss of £0.4 million from a £0.4 million profit. The statutory pre-tax loss was £4.4 million, and the loss after tax of £5.8 million included a £3.0 million Goodwill Impairment and a £1.4 million write-off of a deferred tax asset. A £0.3 million bad Debt provision related to a distributor in the Americas.
Cash and deposits fell to £2.6 million from £4.9 million, reflecting a £1.2 million operating cash outflow, and total Equity roughly halved to £5.7 million. The company had no short-term borrowings at the year-end. The directors adopted the Going Concern basis, citing a reverse stress test that suggested cash would last even if revenue fell a further 15% and gross margin deteriorated, after mitigating actions. No Dividend was reported.
Sector and index context
Cambridge Nutritional Sciences (LSE:CNSL) is one of the smaller healthcare names within the FTSE AIM All Share Index. The diagnostics sector has faced tighter regulation in Europe, and the company is working on compliance with the EU In Vitro Diagnostic Regulation, with completion targeted for 2027. Management has said resources are sufficient for that project.
Key risks
Reliance on distributors leaves revenue exposed to the loss of individual partners, as last year showed. Cash has been falling, so a further decline in sales could put pressure on the balance sheet. Regulatory compliance costs and timetables, plus Credit risk from overseas distributors, are additional concerns.
What to watch next
Investors will look at the half-year figures for signs that restructuring savings, which management expected to show up in the current financial year, are stabilising losses. Key measures include revenue trends by product and region, cash burn, progress with new distributors and the IVDR programme timetable.






Please wait processing your request...